166 related articles for article (PubMed ID: 29274140)
1. JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease.
Tefferi A; Lavu S; Mudireddy M; Lasho TL; Finke CM; Gangat N; Pardanani A; Hanson CA; Mannarelli C; Guglielmelli P; Vannucchi AM
Am J Hematol; 2018 Aug; 93(4):E93-E96. PubMed ID: 29274140
[No Abstract] [Full Text] [Related]
2. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
Maddali M; Kulkarni UP; Ravindra N; Jajodia E; Arunachalam AK; Suresh H; Venkatraman A; George B; Mathews V; Balasubramanian P
Ann Hematol; 2020 May; 99(5):983-989. PubMed ID: 32277273
[TBL] [Abstract][Full Text] [Related]
3. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
4. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
6. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
7. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
8. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
9. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Schnittger S; Bacher U; Haferlach C; Geer T; Müller P; Mittermüller J; Petrides P; Schlag R; Sandner R; Selbach J; Slawik HR; Tessen HW; Wehmeyer J; Kern W; Haferlach T
Haematologica; 2009 Mar; 94(3):414-8. PubMed ID: 19252176
[TBL] [Abstract][Full Text] [Related]
10. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
11. Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience.
Haider M; Gangat N; Hanson C; Tefferi A
Am J Hematol; 2016 May; 91(5):E296-7. PubMed ID: 26875150
[No Abstract] [Full Text] [Related]
12. Distinctive features of polycythaemia vera in New Zealand Polynesians.
Hanna MZ; Kalev-Zylinska ML; Jackson SR; Royle G; Blacklock HA
N Z Med J; 2018 Sep; 131(1482):38-45. PubMed ID: 30235191
[TBL] [Abstract][Full Text] [Related]
13. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates.
Patnaik MM; Knudson RA; Gangat N; Hanson CA; Pardanani A; Tefferi A; Ketterling RP
Eur J Haematol; 2010 Jun; 84(6):518-24. PubMed ID: 20331734
[TBL] [Abstract][Full Text] [Related]
14. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
[TBL] [Abstract][Full Text] [Related]
15. JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera.
Röthlisberger B; Huber A; Bargetzi M; Mendez A; Heizmann M
Leuk Lymphoma; 2008 Mar; 49(3):586-8. PubMed ID: 18297539
[No Abstract] [Full Text] [Related]
16. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis.
Pardanani A; Lasho TL; Finke CM; Tefferi A
Am J Hematol; 2011 Aug; 86(8):701-2. PubMed ID: 21674576
[No Abstract] [Full Text] [Related]
17. Evaluation of Janus Kinase 2 Exon 12 Mutations in Patients With JAK2V617F-negative Polycythemia Vera.
Khosravi S; Chahardouli B; Ebrahimi P; Babaei FN; Alimoghadam K; Rostami S
Hematol Oncol Stem Cell Ther; 2024 Mar; 17(2):154-158. PubMed ID: 38560972
[No Abstract] [Full Text] [Related]
18. The role of a low erythropoietin level in the diagnosis of JAK2 exon 12-mutated polycythemia vera.
Langabeer SE
Blood Cells Mol Dis; 2020 Feb; 80():102377. PubMed ID: 31655393
[No Abstract] [Full Text] [Related]
19. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
20. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
Spivak JL
Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
